Neurocrine Biosciences delivered its biggest single-day gain in recent memory on November 3, jumping 13.4% to $164.85 after Q3 results, leaving a rebuilt short position badly offside. Short interest had climbed steadily through October, rising 25% over the month to reach 6.56 million shares, equal to 6.6% of the free float. That was the highest level in at least a year, a sustained…
NBIX short interest surges 21.8% in one week to 5.3% of float, as stock rallies ahead of earnings.
Key data as of 5 Nov 2026
Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NBIX — free to start on ORTEX.
Sign up for free →Open NBIX on ORTEX